Dr. Yolande Saab
Executive Director
PharmD, PhD in Pharmacogenomics
Dr. Yolande Saab leads the PharmacoGeNomics Institute for Research and Education (PGNI), bringing more than 20 years of experience in pharmacogenomics research and education. Her work encompasses pharmacogenomics scholarship, scientific leadership, and advancing equitable access to pharmacogenomic knowledge and applications.
Scholarship
Selected publications
- Yolande Saab, Zahi Nakad. Validating the accuracy of mathematical model-based pharmacogenomics dose prediction with real-world data. European Journal of Clinical Pharmacology. 2025. DOI
- Zahi Nakad, Yolande Saab. Precision dosing for patients on tricyclic antidepressants. Pharmacogenetics and Genomics. 2024; 34(4). DOI
- Yolande Saab, Zahi Nakad. A software tool to adjust codeine dose based on CYP2D6 gene-pair polymorphisms and drug-drug interactions. The Pharmacogenomics Journal. 2023. DOI
- Yolande Saab, et al. Association of the ACE and AGT gene polymorphisms with global disparities in COVID-19-related deaths. Pharmacogenetics and Genomics. 2023; 33(3):41–50. DOI
- Yolande Saab, et al. Detection of impurities in acetaminophen intravenous and oral formulations: Health-risk assessment. Microchemical Journal. 2024; 207:112019. DOI
Correspondence: ysaab@pgni.org